MedPage Today, Milwaukee Journal Sentinel, October 15, 2016. Diana Zuckerman, president of the National Center for Health Research noted there is another factor arguing against the use of drugs to treat overactive bladder. “All of these drugs have the potential for serious risk,” she said. “So what’s the actual benefit? To weigh that against risks that can be serious, it’s pretty unimpressive.”
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug
Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.
Read More »Anthem Declines to Cover Sarepta Drug for Duchenne, Citing Doubts over Data
STAT News, October 7, 2016. One of the nation’s largest health insurers has decided not to cover a controversial Duchenne muscular dystrophy drug because its FDA approval was not based on scientific evidence that it works. This is what NCHR predicted would happen.
Read More »Obama Extends Controversial Program for Rare Pediatric Drugs
STAT News, September 30, 2016. Friday, President Barack Obama signed into law a bill that will briefly extend a voucher program that rewards drug makers for rare pediatric medicines.
Read More »Furor Over Drug Prices Puts Patient Advocacy Groups in Bind
The New York Times, September 27, 2016. Public anger over the cost of medical products has burned hot for a year, coursing through social media, popping up on the presidential campaign, and erupting in a series of congressional hearings, including one last week over the rising price of the allergy treatment EpiPen.
Read More »